.@Novartis CEO confirmed what health experts and policymakers have raised as a concern — direct-to-consumer (DTC) ads drive up sales and utilization of high-priced brand-name drugs. “It takes six months for DTC to have an impact.” More:

.@Merck’s strategy on blockbuster cancer drug Keytruda provides a case study in Big Pharma’s patent abuse. Get the latest:

ICYMI: @JNJNews reported expectation beating earnings after hiking prescription drug prices 35 times last year. Get the numbers:

ICYMI: @Merck indicated the drug maker will expedite an anti-competitive strategy designed to extend exclusivity and monopoly pricing on its blockbuster cancer drug Keytruda. Read more:

RT @ChuckGrassley: Tired of all those pharmaceutical commercials on tv? They don’t even show the price of the drug Rx prices need more suns…

RT @SenatorDurbin: Big Pharma’s incessant TV ads fuel high prices by pushing patients to the most expensive Rx drugs. But they always keep…

.@icer_review's new analysis will help shine a light on Big Pharma's increasingly out-of-control launch prices on newly approved prescription drugs. More here:

ICYMI: @icer_review announced it will issue a new annual analysis – the “Launch Price and Access Report” – to examine launch prices, affordability and access for prescription drugs. More here ��️

ICYMI: New data from @AARPpolicy on #BigPharma’s egregious price hikes on top-selling blockbusters in Medicare Part D. According to the new report, these price hikes “greatly exceeded the corresponding rate of general inflation.” More:

🚨BREAKING: @AARPpolicy reports brand name drug companies hiked prices on Medicare Part D’s top 25 drugs by an average of 98% — or nearly double — since they entered the market. America’s seniors pay the price of #BigPharma’s egregious price hikes.

#BigPharma makes a tradition of ringing in each new year with egregious price hikes on hundreds of brand name drugs. This January is no different, with a median increase of 4.5% for their price hikes in the first week of January — far outpacing inflation (2.7%). See more:

ICYMI: #BigPharma once again kicked off the year with price hikes on brand name drugs outpacing inflation. Manufacturers set the price, hike the price to boost profits and block competition to keep prices high. Get the facts:

#BigPharma is back at it, ringing in 2025 with egregious price hikes outpacing the rate of inflation. Learn more:

Read our statement on the recent passage of government funding legislation without the inclusion of bipartisan, market-based solutions to hold Big Pharma accountable and lower drug prices ⬇️

#BigPharma’s profits are 10x higher than others in the Rx supply chain. Congress should pass Cornyn-Blumenthal to hold Big Pharma accountable for patent abuse that keeps prices high. Learn more:

We encourage the full Congress to swiftly pass Cornyn-Blumenthal and Q1/Q2 reforms as positive first steps toward cracking down on Big Pharma’s anti-competitive tactics and fostering greater competition in the marketplace to lower prices for consumers.

Big Pharma’s anti-competitive tactics are designed to keep drug prices high. Congress has the power to hold them accountable by passing Cornyn-Blumenthal NOW.

#BigPharma’s patent abuse schemes are designed to protect their profits (not innovation) and extend monopolies to block competition on their blockbuster drugs. Cornyn-Blumenthal is a critical solution to hold Big Pharma accountable to lower drug prices.

Congress MUST pass Cornyn-Blumenthal to hold Big Pharma accountable for its continued abuses that exploit patent thickets to block competition, extend monopolies & increase drug prices. We need urgent action to pass this bipartisan solution NOW.

ICYMI: "@AARP Urges Passage of Prescription Drug Legislation by Year’s End." More on why Congress MUST hold #BigPharma accountable by passing Cornyn-Blumenthal before it's too late ⤵️